Literature DB >> 20975742

Functional role of chemokines in liver disease models.

Hacer Sahin1, Christian Trautwein, Hermann E Wasmuth.   

Abstract

Chemokines are a class of small cytokine-like molecules that orchestrate immune cell infiltration into the liver in response to acute and chronic injuries. Apart from their chemotactic effect, however, chemokines seem to mediate many other aspects of liver diseases, including a direct activation of stellate cells, the modulation of hepatocyte proliferation and angiogenesis. The identification of specific biological functions for chemokines in liver diseases has been hampered by the finding that resident and infiltrating cells in the liver are often a source, as well as a target, of chemokines. Furthermore, chemokines might cause differing effects depending on the etiology of liver damage, their local concentrations and their ability to form multimers and heterodimers. Nevertheless, the functions of a number of important chemokines and their associated receptors have been identified in both in vivo and in vitro studies. Indeed, harmful (proinflammatory, profibrogenic) and beneficial (antifibrogenic, antiangiogenic) effects of chemokines have been discovered in experimental liver disease models. In this Review, the current knowledge of chemokines in experimental liver disease models is summarized. Advances that might lead to preclinical applications are discussed, as are the roles of chemokine receptors as promising pharmacologically targetable molecules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20975742     DOI: 10.1038/nrgastro.2010.168

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  98 in total

1.  The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes.

Authors:  Karlin Raja Karlmark; Henning W Zimmermann; Christoph Roderburg; Nikolaus Gassler; Hermann E Wasmuth; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 2.  Fine-tuning leukocyte responses: towards a chemokine 'interactome'.

Authors:  Christian Weber; Rory R Koenen
Journal:  Trends Immunol       Date:  2006-05-05       Impact factor: 16.687

3.  Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells.

Authors:  F Marra; R G Romanelli; C Giannini; P Failli; S Pastacaldi; M C Arrighi; M Pinzani; G Laffi; P Montalto; P Gentilini
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice.

Authors:  Tomonori Aoyama; Sayaka Inokuchi; David A Brenner; Ekihiro Seki
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

5.  Role of monocytes and macrophages in experimental and human acute liver failure.

Authors:  Lucia A Possamai; Charalambos Gustav Antoniades; Quentin M Anstee; Alberto Quaglia; Diego Vergani; Mark Thursz; Julia Wendon
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

6.  Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice.

Authors:  Elena Zamara; Sara Galastri; Sara Aleffi; Ilaria Petrai; Manuela Aragno; Raffaella Mastrocola; Erica Novo; Cristiana Bertolani; Stefano Milani; Francesco Vizzutti; Alessandro Vercelli; Massimo Pinzani; Giacomo Laffi; Giorgio LaVilla; Maurizio Parola; Fabio Marra
Journal:  J Hepatol       Date:  2006-10-23       Impact factor: 25.083

7.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3.

Authors:  Dianhua Jiang; Jiurong Liang; Jennifer Hodge; Bao Lu; Zhou Zhu; Shuang Yu; Juan Fan; Yunfei Gao; Zhinan Yin; Robert Homer; Craig Gerard; Paul W Noble
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 8.  Chemokine receptor antagonists: Part 1.

Authors:  James E Pease; Richard Horuk
Journal:  Expert Opin Ther Pat       Date:  2009-01       Impact factor: 6.674

9.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

10.  Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver.

Authors:  Andrew P Holt; Emma L Haughton; Patricia F Lalor; Andrew Filer; Christopher D Buckley; David H Adams
Journal:  Gastroenterology       Date:  2008-10-15       Impact factor: 22.682

View more
  30 in total

Review 1.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 2.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Fibrosis-dependent mechanisms of hepatocarcinogenesis.

Authors:  David Y Zhang; Scott L Friedman
Journal:  Hepatology       Date:  2012-06-29       Impact factor: 17.425

4.  Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis.

Authors:  Daniel Heinrichs; Marie-Luise Berres; Melanie Coeuru; Meike Knauel; Andreas Nellen; Petra Fischer; Claudia Philippeit; Richard Bucala; Christian Trautwein; Hermann E Wasmuth; Jürgen Bernhagen
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

5.  Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment.

Authors:  Juanjuan Zhao; Zheng Zhang; Yan Luan; Zhengsheng Zou; Yanling Sun; Yonggang Li; Lei Jin; Chunbao Zhou; Junliang Fu; Bin Gao; Yangxin Fu; Fu-Sheng Wang
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

6.  Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74.

Authors:  Daniel Heinrichs; Meike Knauel; Christian Offermanns; Marie-Luise Berres; Andreas Nellen; Lin Leng; Petra Schmitz; Richard Bucala; Christian Trautwein; Christian Weber; Jürgen Bernhagen; Hermann E Wasmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

7.  Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.

Authors:  Gina Song; David B Darr; Charlene M Santos; Mark Ross; Alain Valdivia; Jamie L Jordan; Bentley R Midkiff; Stephanie Cohen; Nana Nikolaishvili-Feinberg; C Ryan Miller; Teresa K Tarrant; Arlin B Rogers; Andrew C Dudley; Charles M Perou; William C Zamboni
Journal:  Clin Cancer Res       Date:  2014-09-17       Impact factor: 12.531

Review 8.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis.

Authors:  Prakash Ramachandran; Antonella Pellicoro; Madeleine A Vernon; Luke Boulter; Rebecca L Aucott; Aysha Ali; Stephen N Hartland; Victoria K Snowdon; Andrea Cappon; Timothy T Gordon-Walker; Mike J Williams; Donald R Dunbar; Jonathan R Manning; Nico van Rooijen; Jonathan A Fallowfield; Stuart J Forbes; John P Iredale
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-24       Impact factor: 11.205

10.  Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.

Authors:  Shuixia Tan; Jing Zhao; Ziyu Sun; Shuangyi Cao; Kongyan Niu; Yedan Zhong; Han Wang; Linyu Shi; Heling Pan; Junhao Hu; Lihui Qian; Nan Liu; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.